reports
BioAtla Reports First Quarter 2024 Financial Results and Highlights Re...
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 data in squamous cell carcinoma of the head and neck (SCCHN) showed multiple confirmed responses and manageable safety profile; anticipate FDA meeting for SCCHN potential registrational trial in 2H 2024Evalstotug (CTLA-4 antibody) Phase 1 study progressing well, anticipate clearing dose-limiting toxicity (DLT) observation period with 1 gram (14.2 mg/kg) in 2Q 2024 and initial Phase 2 monotherapy data readout on track for 2Q 2024 and in combination with pembrolizumab...
HCI Group Reports First Quarter 2024 Results
HCI Group Reports First Quarter 2024 Results First Quarter Pre-Tax Income of $77.4 millionFirst Quarter Diluted EPS of $3.81First Quarter Gross Loss Ratio of 31.1% TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- HCI Group, Inc. (NYSE:HCI), a holding company with operations in homeowners insurance, information technology services, real estate, and reinsurance, reported pre-tax income of $77.4 million and net income of $57.0 million, or $3.81 diluted earnings per share, in the first quarter of 2024, compared with net income of $17.8 million, or $1.54 diluted earnings per share, in the first ...
BioAtla to Participate in the Citizens JMP Life Sciences Conference
BioAtla to Participate in the Citizens JMP Life Sciences Conference SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the Citizens JMP Life Sciences Conference, to be held in New York, NY May 13-14, 2024. Format: Fireside chat and scheduled one-on-one investor meetingsDate: Monday, ...
- Jonathan Moreland
RHP RYMAN HOSPITALITY PROPERTIES INC.
HUBB HUBBELL INCORPORATED CLASS B
ECL ECOLAB INC.
CTRN CITI TRENDS INC.
HRTG HERITAGE INSURANCE HOLDINGS INC.
EFR ENERGY FUELS
HTLD HEARTLAND EXPRESS INC.
CRVS CORVUS PHARMACEUTICALS
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
EAF GRAFTECH INTERNATIONAL
FRAF FRANKLIN FINANCIAL SERVICES CO.
HQL TEKLA LIFE SCIENCES INVESTORS
CZR CAESARS ENTERTAINMENT INC
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
TDUP THREDUP INC.
TBBK THE BANCORP
VPV INC.
MEGI INVESCO PA VALUE MUNI INC TST
NPCT MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
ASGI NUVEEN CORE PLUS IMPACT FD
DBD ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
DIEBOLD NIXDORF INCORPORATED
BioAtla to Announce First Quarter 2024 Financial Results and Provide B...
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024 SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 14, 2024 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024 and provide business highlights. Conference Call and Webcas...
BioAtla Announces FDA Clearance of Investigational New Drug Applicatio...
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate BA3361 (CAB-Nectin-4) antibody drug conjugate (ADC) for ...
HCI Group Declares Quarterly Cash Dividend
HCI Group Declares Quarterly Cash Dividend TAMPA, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- The board of directors of (NYSE: HCI), a holding company with operations in homeowners insurance, information technology services, real estate, and reinsurance, has declared a regular quarterly cash dividend in the amount of 40 cents per common share. The dividend is scheduled to be paid June 21, 2024 to shareholders of record at the close of business May 17, 2024. About HCI Group, Inc.HCI Group, Inc. owns subsidiaries engaged in diverse, yet complementary business activities, including homeowners...
Donegal Group Inc. Announces First Quarter 2024 Results
Donegal Group Inc. Announces First Quarter 2024 Results MARIETTA, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- Donegal Group Inc. (NASDAQ: DGICA) and (NASDAQ: DGICB) today reported its financial results for the first quarter of 2024. Significant Items for First Quarter of 2024 (all comparisons to first quarter of 2023): Net premiums earned increased 5.8% to $227.7 millionNet premiums written1 increased 6.0% to $251.4 millionCombined ratio of 102.4%, compared to 101.2%Net income of $6.0 million, or $0.18 per diluted Class A share, compared to $5.2 million, or $0.16 per diluted Class A shareAn...
BioAtla Announces Upcoming Poster Presentation at the 2024 American So...
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024....
HCI Group Announces Five-Year Employment Agreement with Chief Executiv...
HCI Group Announces Five-Year Employment Agreement with Chief Executive Officer TAMPA, Fla., April 23, 2024 (GLOBE NEWSWIRE) -- (NYSE: HCI), a holding company with operations in homeowners insurance, information technology services, real estate, and reinsurance, announced today that it has entered into a new Executive Employment Agreement with its Chairman and Chief Executive Officer, Paresh Patel. The new agreement secures Mr. Patel’s leadership for at least an additional five years. Mr. Patel’s proven success over HCI’s 17-year history has seen the Company grow to over $1 billion in a...
Donegal Group Inc. Announces Increase in Quarterly Dividend
Donegal Group Inc. Announces Increase in Quarterly Dividend MARIETTA, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Donegal Group Inc. (NASDAQ:DGICA) and (NASDAQ:DGICB) reported today that its board of directors declared a regular quarterly cash dividend of $0.1725 per share of the Company’s Class A common stock and $0.155 per share of the Company’s Class B common stock. The dividends are payable on May 22, 2024 to stockholders of record as of the close of business on May 8, 2024. These dividends represent percentage increases of 1.5% for the Company’s Class A common stock and 1.6% for the C...
HCI Group Sets First Quarter 2024 Earnings Call for Wednesday, May 8, ...
HCI Group Sets First Quarter 2024 Earnings Call for Wednesday, May 8, 2024, at 4:45 p.m. ET TAMPA, Fla., April 11, 2024 (GLOBE NEWSWIRE) -- (NYSE: HCI), a holding company with operations in homeowners insurance, information technology services, real estate, and reinsurance, will hold a conference call on Wednesday, May 8, 2024, at 4:45 p.m. Eastern time to discuss results for the first quarter ended March 31, 2024. Financial results will be issued in a press release the same day after the close of the market. HCI management will host the presentation, followed by a question-and-answer p...
HCI Group Inc: 2 directors
A director at HCI Group Inc bought 1,000 shares at 114.900USD and the significance rating of the trade was 40/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Donegal Group Inc. Announces Release Date for First Quarter 2024 Resul...
Donegal Group Inc. Announces Release Date for First Quarter 2024 Results MARIETTA, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Donegal Group Inc. (NASDAQ:DGICA) and (NASDAQ:DGICB) announced today that it plans to release its results for first quarter ended March 31, 2024 on Thursday, April 25, 2024, before the opening of regular trading on the NASDAQ Stock Market. The Company will provide a supplemental investor presentation in the Investors section of its website at , concurrently with its earnings press release. At approximately 8:30 am ET on Thursday, April 25, 2024, the Company will make...
HCI Group Sets 2024 Annual Shareholders Meeting and Record Date
HCI Group Sets 2024 Annual Shareholders Meeting and Record Date TAMPA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- (NYSE: HCI), a holding company with operations in homeowners insurance, information technology services, real estate, and reinsurance, will hold its Annual Meeting of Shareholders on Tuesday, June 11, 2024, at 3:00 p.m. Eastern time in the 1st Floor Auditorium of HCI’s headquarters at 3802 Coconut Palm Drive, Tampa, Florida. Shareholders of record at the close of business on Monday, April 15, 2024, will be entitled to vote and attend the meeting. Items of business will include...
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results an...
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data readout anticipated in 2Q 2024 and in combination with pembrolizumab in 2H 2024CAB-ROR2 (BA3021) Phase 2 melanoma and squamous cell carcinoma of the head and neck (SCCHN) clinical trials fully enrolled; on track for data readouts in 2Q 2024CAB-AXL (BA3011) Phase 2 potentially registrational study in undifferentiated pleomorphic sarcoma (UPS) on trac...
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Result...
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024 SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, March 26, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2023 and provide business hi...
HCI Group Reports Fourth Quarter and Full Year 2023 Results
HCI Group Reports Fourth Quarter and Full Year 2023 Results Fourth Quarter Diluted EPS of $3.40Fourth Quarter Gross Loss Ratio of 30.4%Fourth Quarter Pre-Tax Income of $54.2 million TAMPA, Fla., March 07, 2024 (GLOBE NEWSWIRE) -- HCI Group, Inc. (NYSE:HCI), a holding company with operations in homeowners insurance, information technology services, real estate, and reinsurance, reported pre-tax income of $54.2 million and net income of $40.9 million, or $3.40 diluted earnings per share, in the fourth quarter of 2023, compared with net income of $2.7 million, or $0.18 diluted earnings pe...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.